Status:
COMPLETED
A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy
Lead Sponsor:
University of Zurich
Collaborating Sponsors:
AlleCure
Conditions:
Rhinoconjunctivitis Due to Grass Pollen Allergy
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Allergen specific immunotherapy (SIT) is the only causative treatment of IgE-mediated allergies. The disadvantages of SIT, however, are the requirement of numerous allergen administrations over three ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Written informed consent
- History of allergic rhino-conjunctivitis in spring and summer
- Age 18 years to 65 years
- Positive skin prick test to grass pollen
- Exclusion criteria:
- Blood donation within previous 30 days
- Surgery within the previous 30 days
- Use of investigational drugs within previous 90 days
- Pregnancy or nursing
- Mastocytosis
- Significant cardiovascular disease
- Hypertension
- Active infectious disease
- Significant hepatic disease
- Significant renal disease
- Significant hematological disorder
- Significant pulmonary disease
- Moderate or severe asthma
- Autoimmune disease
- History of malignancy.
- Contraindicated medications were immunosuppressive agents, beta-blockers, ACE-inhibitors, and tricyclic antidepressants.
Exclusion
Key Trial Info
Start Date :
June 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2005
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT00470457
Start Date
June 1 2001
End Date
March 1 2005
Last Update
December 3 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinic for Dermatology University Hospital of Zurich
Zurich, Switzerland